News
RUMMAGING through her packed wardrobe Vivienne Joy struggles to find something that still fits. Since starting Mounjaro three ...
Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.
Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.
Women who use an oral contraceptive might want to consider using a back-up method after starting a weight loss drug.
The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...
A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...
WEIGHT loss jabs have been a godsend for people in the UK living with obesity. But despite 1.5 million people using the ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.
As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...
Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...
Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results